- Report
- March 2024
- 189 Pages
Global
From €3274EUR$3,374USD£2,823GBP
€3638EUR$3,749USD£3,137GBP
- Report
- February 2024
- 175 Pages
Global
From €4852EUR$5,000USD£4,184GBP
- Report
- February 2024
- 168 Pages
Global
From €3493EUR$3,600USD£3,012GBP
- Report
- August 2023
- 116 Pages
Global
From €4755EUR$4,900USD£4,100GBP
- Report
- June 2023
- 76 Pages
Global
From €3391EUR$3,495USD£2,925GBP
- Report
- February 2024
- 140 Pages
Global
From €4609EUR$4,750USD£3,975GBP
- Report
- June 2023
- 840 Pages
Global
From €3493EUR$3,600USD£3,012GBP
- Report
- February 2024
- 175 Pages
Global
From €4852EUR$5,000USD£4,184GBP
- Report
- February 2024
- 250 Pages
Global
From €4852EUR$5,000USD£4,184GBP
- Report
- September 2023
- 149 Pages
Global
From €2425EUR$2,499USD£2,091GBP
- Report
- February 2024
- 115 Pages
Global
From €4609EUR$4,750USD£3,975GBP
- Report
- October 2023
- 170 Pages
Global
From €4755EUR$4,900USD£4,100GBP
- Report
- October 2019
- 170 Pages
Global
From €2523EUR$2,600USD£2,176GBP
- Report
- March 2018
- 255 Pages
Global
From €2523EUR$2,600USD£2,176GBP
- Report
- July 2022
- 600 Pages
Global
From €3202EUR$3,300USD£2,761GBP
- Report
- July 2021
- 155 Pages
Global
From €2668EUR$2,750USD£2,301GBP
€5337EUR$5,500USD£4,602GBP
- Report
- November 2020
- 241 Pages
United States
From €2319EUR$2,390USD£2,000GBP
- Report
- September 2022
- 134 Pages
From €2038EUR$2,100USD£1,757GBP
€2911EUR$3,000USD£2,510GBP
- Report
- September 2022
- 150 Pages
Middle East, Africa
From €2038EUR$2,100USD£1,757GBP
€2911EUR$3,000USD£2,510GBP
- Report
- September 2022
- 157 Pages
Europe
From €2038EUR$2,100USD£1,757GBP
€2911EUR$3,000USD£2,510GBP
The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer.
The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries.
Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more